^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    INV-88

    i
    Other names: INV-88, INV88, INV 88
    Associations

    News

    Trials
    Company:
    Innovimmune Biotherap
    Drug class:
    MIF inhibitor
    Related drugs:
    Associations

    News

    Trials
    over2years
    Design and discovery of novel oral INV-88 macrophage migration inhibitory factor (MIF) inhibitors: Potent anti-tumor activity in vitro and in vivo (AACR 2022)
    The data presented highlight the potential therapeutic utility of pharmacological MIF inhibition with oral INV-88 new chemical entities as a novel immunotherapeutic treatment modality for cancer.
    Preclinical • IO biomarker
    |
    BCL2 (B-cell CLL/lymphoma 2) • CD74 (CD74 Molecule) • IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • CXCL8 (Chemokine (C-X-C motif) ligand 8) • CD44 (CD44 Molecule) • CASP3 (Caspase 3) • MIF (Macrophage Migration Inhibitory Factor) • CASP7 (Caspase 7) • IL1B (Interleukin 1, beta)
    |
    MIF overexpression • CXCL8 expression • IL6 expression
    |
    INV-88